Protara Therapeutics Inc (TARA) Stock Analysis

Protara Therapeutics Inc (TARA) is a publicly traded company in the HEALTHCARE sector. It trades at $4.34, carries a market capitalization of $254.04M. This page summarizes the public market data, fundamentals, and frequently asked questions for TARA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Protara Therapeutics Inc currently has a Neutral sentiment score of -0.03.

About Protara Therapeutics Inc

Protara Therapeutics, Inc. (TARA) is a clinical-stage biopharmaceutical company headquartered in New York, dedicated to developing innovative therapies for cancer and rare diseases. The company's proprietary product candidates utilize advanced drug delivery technologies designed to improve therapeutic outcomes for patients with significant unmet medical needs. With a strong pipeline supported by strategic collaborations, Protara is well-positioned to advance transformative treatments while pr...

GNG Research Analysis

GNG Research scores Protara Therapeutics Inc (TARA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for TARA.

Frequently Asked Questions

Does TARA pay dividends?

Protara Therapeutics Inc (TARA) does not currently pay a regular dividend.

What is TARA's market cap?

Protara Therapeutics Inc (TARA) has a market capitalization of $254.04M with a current stock price of $4.34.